Vera Therapeutics

VERA

Market cap $2.9B

Positive Phase 3 data from ORIGIN 3 study of atacicept in IgA nephropathy (IgAN) presented at American Society of Nephrology (ASN) Kidney Week and published in the New England Journal of Medicine U.S. Food and Drug Administration (FDA) granted priority review to Biologics License Application (BLA) for atacicept with Prescription Drug User Fee Act (PDUFA) date of July 7, 2026; potential commercial launch of atacicept expected in mid-2026 Strong balance sheet bolstered by equity and debt financings in 2025 expected to be sufficient to fund company beyond atacicept approval and U.S. commercial launch BRISBANE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the full year ended December 31, 2025.

BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present and participate in one-on-one meetings at upcoming investor conferences.

Vera Therapeutics is downgraded from 'Strong Buy' to 'Hold' due to intensifying competition in the IgAN space. VERA's atacicept met the primary endpoint in the phase 3 ORIGIN trial, enabling a BLA submission and Priority Review with a PDUFA date of July 7, 2026. Competitive risks are heightened by Otsuka's VOYXACT, which shows superior proteinuria reduction and more convenient dosing.

BRISBANE, Calif., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on February 2, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 11,500 shares of Class A common stock and restricted stock units (RSUs) underlying 5,750 shares of Class A common stock to two (2) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan).

BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Matt Skelton to Chief Commercial Officer, effective immediately.

The consensus price target hints at a 53.1% upside potential for Vera Therapeutics (VERA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Vera Therapeutics, Inc. (VERA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

BRISBANE, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on January 5, 2026, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 228,750 shares of Class A common stock and restricted stock units (RSUs) underlying 116,000 shares of Class A common stock to eighteen (18) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan).

The biotech has formally submitted a biologics license application to the FDA for its kidney disease drug. It has been accepted for priority review by the healthcare industry regulator.

Vera Therapeutics Inc. (NASDAQ: VERA) stock rose Wednesday after the U.S. Food and Drug Administration (FDA) accepted the company's atacicept Biologics License Application (BLA) for Priority Review.